Michiel J. van Esdonk

First-in-Human Assessment of cRGD-ZW800-1, a Zwitterionic, Integrin-Targeted, Near-Infrared Fluorescent Peptide in Colon Carcinoma

Kim S. de Valk, Marion M. Deken, Henricus J.M. Handgraaf et al. · Clinical Cancer Research · 2020 · 100 citations

Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy

Vasudev Kantae, Elke H. J. Krekels, Michiel J. van Esdonk et al. · Metabolomics · 2016 · 90 citations · Full text

Translational Medicine, Pharmacokinetic Modeling, Pharmacodynamics +13

A zwitterionic near-infrared fluorophore for real-time ureter identification during laparoscopic abdominopelvic surgery

Kim S. de Valk, Henricus J.M. Handgraaf, Marion M. Deken et al. · Nature Communications · 2019 · 69 citations · Full text

Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement

Michelle Mellion, Lucienne Ronco, Cécile L. Berends et al. · British Journal of Clinical Pharmacology · 2021 · 37 citations · Full text

Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery <i>vs</i>. subcutaneous administration: results of a randomized controlled clinical trial

Justin Jacobse, Wouter ten Voorde, Anushka Tandon et al. · British Journal of Clinical Pharmacology · 2021 · 26 citations · Full text